Gastrointestinal Healing Ulcer Repair: New blood vessel formation brings repair cells and nutrients to ulcer margins Mucosal Regeneration: Enhanced blood supply supports rapid epithelial turnover Fistula Healing: Angiogenesis promotes granulation tissue formation and closure Tendon and Ligament Repair Hypovascular Tissues: Tendons have poor blood supply, limiting natural healing BPC-157 Effect: Increased vascularity delivers tenocytes and collagen precursors Functional Outcomes: Improved tensile strength and reduced healing time in animal models Muscle Regeneration Satellite Cell Activation: Blood vessel formation brings growth factors that activate muscle stem cells Fiber Repair: Enhanced nutrient delivery supports protein synthesis Crush Injuries: BPC-157 accelerates recovery from muscle trauma Bone Healing Fracture Repair: Angiogenesis is essential for callus formation and mineralization Osteoblast Activity: Enhanced blood supply supports bone-forming cell function Segmental Defects: Improved healing of critical-sized bone defects Beyond VEGF: The Growth Factor Network BPC-157's healing effects involve multiple growth factors beyond VEGF
Headache 58 , 4552 (2018)
Conservative approach (better tolerated) Slower escalation: Week 1-6: 0.6mg weekly Week 7-12: 1.2mg weekly Week 13-18: 1.8mg weekly Week 19+: 2.4mg weekly (or stay at 1.8mg) Benefits: Fewer side effects Better tolerability Good for GI-sensitive people Still effective (slightly less weight loss) Maintenance at lower dose: Some maintain at 1.8mg or 2.0mg 8-10% weight loss still achievable Better long-term sustainability More affordable Aggressive protocol (maximum weight loss) Higher doses (some trials): Week 1-4: 0.6mg weekly Week 5-8: 1.2mg weekly Week 9-12: 2.4mg weekly (faster) Week 13-16: 3.0mg weekly Week 17+: 4.5mg weekly (maximum) Warning: Higher side effect risk Nausea very common at 4.5mg Not necessary for most people Only if excellent tolerability Research setting primarily Expected additional benefit: 4.5mg: ~11-12% vs 2.4mg: ~10% Modest additional loss May not justify side effects Individualized decision Combination with semaglutide dosing CagriSema protocol: Start both simultaneously OR add cagrilintide to existing semaglutide Semaglutide: Titrate to 2.4mg over 16-20 weeks Cagrilintide: Titrate to 2.4mg over 12-16 weeks Both weekly injections (can be same day) Sequential approach (if already on semaglutide): Stable on semaglutide 2.4mg for 4+ weeks Add cagrilintide starting 0.6mg weekly Titrate cagrilintide to 2.4mg over 12 weeks Continue both Expected results: 15-25% body weight loss Superior to either alone Well-documented synergy See our cagrilintide and semaglutide , semaglutide dosage calculator , and tirzepatide dosing guide guides
expands glutathione production capacity by over 15% to meet global demand Kyowa Hakko Bio Co., Ltd., a leading manufacturer in the glutathione sector, announced a significant expansion of its production capacity in early 2024, increasing output by more than 15% year-over-year to address surging global demand for glutathione in pharmaceuticals and nutraceuticals
Now you, unfortunately, cannot readily measure glutathione levels
